Download PDF

1. Company Snapshot

1.a. Company Description

Aker BioMarine AS develops, produces, and sells krill-derived ingredients for nutraceutical, dietary supplement, and animal feed applications in Norway, the Americas, the Asia Pacific, Europe, the Middle East, and Africa.It operates through two segments, Ingredients and Brands.It provides Superba, a krill-based ingredients for nutraceutical, including phospholipid complex of choline, omega-3s, and antioxidant astaxanthin; QRILL Aqua, a krill-based ingredients for aquaculture; and QRILL Pet, a krill-based ingredients animal feed application.


The company also offers LYSOVETA, a delivery platform based on LPC-bound EPA and DHA from krill; and INVI, a hydrolyzed protein isolate for food and beverage applications.In addition, it distributes human health and nutrition products, and natural supplements, as well as provides AION, a circular solution provider that recycles waste and re-use materials.The company was founded in 2006 and is headquartered in Lysaker, Norway.


Aker BioMarine ASA is a subsidiary of Aker ASA.

Show Full description

1.b. Last Insights on AKBM

Aker BioMarine AS's recent performance was driven by a 12% revenue increase and a 41% rise in EBITDA, as reported during the Q2 2025 earnings call. The company's ability to navigate production and market challenges has been a significant factor in its success. Furthermore, the strong revenue growth and EBITDA expansion indicate a robust operational performance, underscoring the company's resilience in a challenging environment.

1.c. Company Highlights

2. Transcript Summary

Unfortunately this company is not part of our coverage yet. But as part of your subscription plan you can request it by clicking just below and we'll process.

Request Coverage

3. NewsRoom

Card image cap

European Stocks Possibly Trading Below Intrinsic Value Estimates In December 2025

Dec -04

Source:

Card image cap

European Stocks That May Be Trading Below Their Estimated Value

Dec -04

Source:

Card image cap

3 European Stocks That May Be Priced Below Their Estimated Value In December 2025

Dec -01

Source:

Card image cap

European Equity Bargains Valued Below Estimated Worth In December 2025

Dec -01

Source:

Card image cap

Aker BioMarine ASA (STU:1PG) Q3 2025 Earnings Call Highlights: Strong Revenue Growth Amid ...

Nov -08

Source:

Card image cap

Aker BioMarine (OB:AKBM) Losses Deepen 15% Annually, Narrative Shifts to Profitability Prospects

Nov -02

Source:

Card image cap

3 Global Stocks Estimated To Be Trading At Discounts Of Up To 38.9%

Oct -21

Source:

Card image cap

European Stocks That Might Be Trading Below Value Estimates In October 2025

Oct -20

Source:

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (10.75%)

6. Segments

Ingredients

Expected Growth: 10%

Aker BioMarine AS's 10% growth is driven by increasing demand for sustainable and eco-friendly krill-based ingredients, expansion into new markets, and growing adoption in the pharmaceutical and nutraceutical industries. Additionally, the company's commitment to sustainable harvesting practices and certifications such as MSC and ISO 14001 contribute to its growth.

Brands

Expected Growth: 12%

Aker BioMarine AS's 12% growth is driven by increasing demand for sustainable and eco-friendly krill-based products, expansion into new markets, and strategic partnerships. The company's commitment to innovation, quality, and sustainability resonates with environmentally conscious consumers, leading to increased brand loyalty and market share.

7. Detailed Products

QRILL Aqua

A sustainable and renewable source of omega-3 fatty acids for the aquaculture industry, improving the health and growth of farmed fish and shrimp.

QRILL Pet

A natural source of omega-3 fatty acids for the pet food industry, supporting the health and well-being of dogs and cats.

QRILL Pro

A high-quality source of omega-3 fatty acids for human nutrition, supporting heart health and brain function.

Lysoveta

A natural and sustainable source of phospholipids for the pharmaceutical and cosmetic industries.

8. Aker BioMarine AS's Porter Forces

Forces Ranking

Threat Of Substitutes

Aker BioMarine AS operates in a niche market with limited substitutes, but the threat of substitutes is still present due to the growing demand for sustainable and eco-friendly products.

Bargaining Power Of Customers

Aker BioMarine AS has a diverse customer base, and no single customer has significant bargaining power, reducing the bargaining power of customers.

Bargaining Power Of Suppliers

Aker BioMarine AS relies on a few key suppliers for raw materials, giving them some bargaining power, but the company's strong relationships with suppliers mitigate this risk.

Threat Of New Entrants

The krill harvesting industry has high barriers to entry, including significant capital requirements and regulatory hurdles, making it difficult for new entrants to join the market.

Intensity Of Rivalry

The krill harvesting industry is highly competitive, with a few large players competing for market share, leading to a high intensity of rivalry.

9. SWOT Analysis

Strength

Weaknesses

Opportunities

Threats

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

Value
Debt Weight 51.74%
Debt Cost 8.12%
Equity Weight 48.26%
Equity Cost 8.12%
WACC 8.12%
Leverage 107.20%

11. Quality Control: Aker BioMarine AS passed 4 out of 9 key points

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

Stock-Card
Fine Foods & Pharmaceuticals N.T.M.

A-Score: 5.7/10

Value: 6.7

Growth: 8.4

Quality: 4.6

Yield: 2.5

Momentum: 4.0

Volatility: 8.0

1-Year Total Return ->

View Full Report
Stock-Card
Bonduelle

A-Score: 5.1/10

Value: 10.0

Growth: 1.2

Quality: 2.7

Yield: 3.8

Momentum: 8.5

Volatility: 4.7

1-Year Total Return ->

View Full Report
Stock-Card
Greencore

A-Score: 4.4/10

Value: 6.2

Growth: 5.7

Quality: 5.0

Yield: 0.6

Momentum: 6.0

Volatility: 3.0

1-Year Total Return ->

View Full Report
Stock-Card
Aker BioMarine

A-Score: 4.3/10

Value: 2.9

Growth: 5.9

Quality: 4.8

Yield: 0.0

Momentum: 10.0

Volatility: 2.3

1-Year Total Return ->

View Full Report
Stock-Card
ARYZTA

A-Score: 4.3/10

Value: 6.1

Growth: 5.7

Quality: 4.2

Yield: 0.0

Momentum: 4.0

Volatility: 6.0

1-Year Total Return ->

View Full Report
Stock-Card
Unibel

A-Score: 4.1/10

Value: 4.4

Growth: 3.0

Quality: 2.8

Yield: 1.2

Momentum: 4.5

Volatility: 8.7

1-Year Total Return ->

View Full Report

Peers Metrics

12.e Scoring Insights

12.f DCF BETA

Parameters

Short Term Growth

Short term Time

Long-Term Growth

WACC

Target Price

91.2$

Current Price

91.2$

Potential

-0.00%

Expected Cash-Flows